Business Context and Reporting Period
This Form 8-K Current Report from Black Diamond Therapeutics, Inc. (BDTX) covers events occurring on June 6, 2024, specifically the Company's 2024 Annual Meeting of Stockholders held in a virtual-only format.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Corporate Actions
- Amendment to Certificate of Incorporation: Stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law. The amendment became effective upon filing with the Delaware Secretary of State on June 6, 2024.
- Board Elections: Two Class I director nominees, Prakash Raman and Mark A. Velleca, were elected to the Board.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results and Management Commentary
As of the record date (April 9, 2024), there were 52,530,334 shares of Common Stock outstanding. A total of 46,716,888 shares were present or represented by proxy, establishing a quorum.
| Proposal | For | Against | Abstain/Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Proposal 1: Elect Prakash Raman | 40,193,088 | - | 56,745 (Withheld) | 6,467,055 |
| Proposal 1: Elect Mark A. Velleca | 38,950,009 | - | 1,299,824 (Withheld) | 6,467,055 |
| Proposal 2: Ratify PwC | 46,676,151 | 31,101 | 9,636 | - |
| Proposal 3: Limit Officer Liability | 39,725,976 | 492,202 | 31,655 | 6,467,055 |
The filing contains no specific management commentary regarding future guidance, risks, or contingencies beyond the standard incorporation by reference to the Proxy Statement.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of liability limitations for officers.
- Review the definitive Proxy Statement filed on April 24, 2024, for detailed background on the director nominees and the rationale for the liability amendment.
- Confirm the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.
- Note that this filing does not contain updated financial data; refer to the most recent 10-Q or 10-K for financial health metrics.